Jason Zemcik, Senior Director of Product Management, TrialCard

The Centers for Medicare and Medicaid Services (CMS) finalized a rule in December 2020 concerning Medicaid Best Price implications for co-pay assistance programs.

On February 23, 2021, TrialCard sponsored a live webcast on this topic, drawing in hundreds of key stakeholders across the biopharma industry. Polling questions asked during the event captured data on how industry leaders view the rule and plan to address it. Several takeaways have emerged from these interactions, which are described in this report.